Navigation Links
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Date:9/2/2008

in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, Inc. ... on gynecologic disease, announced today that the Company ... including Oracle Investment Management, Jack W. Schuler ... Total proceeds were $10.5 million, before offering expenses.  ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... Biopharmaceuticals Ltd. (Nasdaq: XTLB , TASE: XTL) today ... regarding the Company,s activities in seeking to acquire potential assets ... XTL. The Company is currently evaluating several merger proposals that ... companies who operate in and outside of the healthcare space. ...
... 23andMe , Inc., an industry leader in ... research company dedicated to the development of treatments for ... in Davos, Switzerland, that they are collaborating to advance ... of the companies to the World Economic Forum, where ...
... dots created by researchers at Canada,s National Institute for ... new level of control over individual electrons, a development ... Composed of a single atom of silicon and measuring ... smallest quantum dots ever created. , Quantum ...
Cached Biology Technology:XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives 223andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases 223andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases 3Smallest ever quantum dots bring real world applications closer 2
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... digital media watermarking and fingerprinting markets. Watermarking aims ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)...  HITLAB SM announced today its completion of a ... to current U.S. Food and Drug Administration (FDA) regulations. ... and smart phone application trials utilizing the highest principles ... is determined to improve global healthcare access, quality, and ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... by the Biotechnology and Biological Sciences Research Council and ... have developed a revolutionary way of capturing a high-resolution ... technology that is attractive for science, industry and consumer ... in standard cameras and digital movie projectors they have ...
... Feb. 12, 2010 -- By taking advantage of a ... for electronics designers, a team led by Oak Ridge ... biological sensor with unprecedented sensitivity. Ultimately, researchers believe ... approaches the theoretical limit, surpassing other state-of-the-art chemical sensors. ...
... Haven, Conn.Yale University scientists have streamlined the process for synthesizing ... and other diseased cells, and have found that they represent ... this week,s online edition of the Journal of the ... family of compounds known as the kinamycins, which are naturally ...
Cached Biology News:Cameras of the future: heart researchers create revolutionary photographic technique 2Cameras of the future: heart researchers create revolutionary photographic technique 3Cameras of the future: heart researchers create revolutionary photographic technique 4New ORNL sensor exploits traditional weakness of nano devices 2Scientists synthesize unique family of anti-cancer compounds 2
CHIMAERIC HUMAN IgA2 ANTI NP...
ANTI NO-TRYPTOPHAN CONJUGATE...
... The Captivate magnetic ... can be used in conjunction ... (C-21473, C-21474, C-21476) or other ... with most 96-well microplates. Cell ...
Protein Phosphorylation...
Biology Products: